AU730818B2 - Use of (+)mefloquine for the treatment of malaria - Google Patents

Use of (+)mefloquine for the treatment of malaria Download PDF

Info

Publication number
AU730818B2
AU730818B2 AU65068/98A AU6506898A AU730818B2 AU 730818 B2 AU730818 B2 AU 730818B2 AU 65068/98 A AU65068/98 A AU 65068/98A AU 6506898 A AU6506898 A AU 6506898A AU 730818 B2 AU730818 B2 AU 730818B2
Authority
AU
Australia
Prior art keywords
medical condition
subject
disorder
trifluoromethyl
piperidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU65068/98A
Other languages
English (en)
Other versions
AU6506898A (en
Inventor
Robin Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704809.4A external-priority patent/GB9704809D0/en
Priority claimed from GBGB9722232.7A external-priority patent/GB9722232D0/en
Priority claimed from GBGB9724263.0A external-priority patent/GB9724263D0/en
Priority claimed from GBGB9724712.6A external-priority patent/GB9724712D0/en
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Publication of AU6506898A publication Critical patent/AU6506898A/en
Assigned to CEREBRUS PHARMACEUTICALS LIMITED reassignment CEREBRUS PHARMACEUTICALS LIMITED Amend patent request/document other than specification (104) Assignors: CEREBRUS LIMITED
Assigned to VERNALIS RESEARCH LIMITED reassignment VERNALIS RESEARCH LIMITED Amend patent request/document other than specification (104) Assignors: CEREBRUS PHARMACEUTICALS LIMITED
Application granted granted Critical
Publication of AU730818B2 publication Critical patent/AU730818B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU65068/98A 1997-03-07 1998-03-06 Use of (+)mefloquine for the treatment of malaria Ceased AU730818B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9704809.4A GB9704809D0 (en) 1997-03-07 1997-03-07 Chemical compounds
GB9704809 1997-03-07
GB9722232 1997-10-21
GBGB9722232.7A GB9722232D0 (en) 1997-10-21 1997-10-21 Chemical compounds
GB9724263 1997-11-17
GBGB9724263.0A GB9724263D0 (en) 1997-11-17 1997-11-17 Chemical compounds
GB9724712 1997-11-21
GBGB9724712.6A GB9724712D0 (en) 1997-11-21 1997-11-21 Chemical compounds
PCT/GB1998/000675 WO1998039003A1 (en) 1997-03-07 1998-03-06 Use of (+)mefloquine for the treatment of malaria

Publications (2)

Publication Number Publication Date
AU6506898A AU6506898A (en) 1998-09-22
AU730818B2 true AU730818B2 (en) 2001-03-15

Family

ID=27451612

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65068/98A Ceased AU730818B2 (en) 1997-03-07 1998-03-06 Use of (+)mefloquine for the treatment of malaria

Country Status (10)

Country Link
US (1) US6664397B1 (enExample)
EP (1) EP0966285B1 (enExample)
JP (1) JP4380800B2 (enExample)
AT (1) ATE225177T1 (enExample)
AU (1) AU730818B2 (enExample)
DE (1) DE69808440T2 (enExample)
DK (1) DK0966285T3 (enExample)
ES (1) ES2185153T3 (enExample)
PT (1) PT966285E (enExample)
WO (1) WO1998039003A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975345A1 (en) * 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
GB0021776D0 (en) 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
GB0406014D0 (en) * 2004-03-17 2004-04-21 Arakis Ltd Pharmaceutical composition and use
US20070032480A1 (en) * 2005-06-14 2007-02-08 The Johns Hopkins University Treatment of ischemia-induced arrhythmias
RU2008135762A (ru) * 2006-02-16 2010-03-27 Де МакЛин Хоспитал Корпорейшн (US) Способы и композиции для лечения болезни паркинсона
US20110039888A1 (en) * 2008-04-21 2011-02-17 Coltart Don M Asymmetric alpha functionalization and alpha, alpha bisfunctionalization of aldehydes and ketones
US8293783B2 (en) * 2009-03-24 2012-10-23 National University Of Singapore Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (COPD)
US8716265B2 (en) 2010-11-18 2014-05-06 Jenrin Discovery, Inc. 4-quinolinemethanols as anti-malarial agents
EP2487157A1 (en) 2011-02-11 2012-08-15 Université de Picardie Jules Verne Enantioselective synthesis method of 4-aminoalcoholquinoline derivatives and the use
RU2015105407A (ru) * 2012-08-09 2016-10-10 Кэн-Файт Биофарма Лтд. Лиганды аденозинового рецептора а3 для применения при лечении половой дисфункции
CN103304538B (zh) * 2013-06-21 2014-12-24 中国人民解放军第四军医大学 右旋甲氟喹的合成
CN107149601B (zh) * 2017-05-25 2020-04-17 中国中医科学院中药研究所 青蒿素类化合物在制备治疗神经病理性疼痛和/或并发症的药物中的应用
US11220482B2 (en) 2017-11-03 2022-01-11 Universite Amiens Picardie Jules Verne Aminopyridinemethanol compounds and their use
CN110507646A (zh) * 2019-09-12 2019-11-29 广州中医药大学(广州中医药研究院) 青蒿素衍生物在制备抗焦虑症的药物或缓解焦虑症的食品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2940443A1 (de) 1979-10-05 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von erythro-(alpha)-2-piperidyl-2,8-bis-(trifluormethyl)-4-chinolin-methanol
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system

Also Published As

Publication number Publication date
EP0966285B1 (en) 2002-10-02
EP0966285A1 (en) 1999-12-29
DK0966285T3 (da) 2002-10-28
ATE225177T1 (de) 2002-10-15
JP4380800B2 (ja) 2009-12-09
HK1024631A1 (en) 2000-10-20
ES2185153T3 (es) 2003-04-16
AU6506898A (en) 1998-09-22
US6664397B1 (en) 2003-12-16
DE69808440T2 (de) 2003-07-10
PT966285E (pt) 2002-12-31
DE69808440D1 (de) 2002-11-07
JP2001526637A (ja) 2001-12-18
WO1998039003A1 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
AU730818B2 (en) Use of (+)mefloquine for the treatment of malaria
US6197788B1 (en) (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
AU2006244074B2 (en) Compounds for modulating TRPV3 function
HU202108B (en) Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
TW200412970A (en) Pharmaceutical composition comprising PDE 5 inhibitor and active ingredients
JP2012051918A (ja) カンナビノイドの新規用途
US20160256447A1 (en) Compounds for modulating trpv3 function
AU2020239746B2 (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
JP2003509371A (ja) ５−ヒドロキシトリプタミン・レセプタ／α２アドレナリン作用性レセプタ拮抗薬組成物の投与による運動障害の処置
US9238033B2 (en) Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine
EP3520788A1 (en) Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis
JP5148478B2 (ja) マラリア治療用のフェロキンとアーテミシニン誘導体との組合せ
JP2021511338A (ja) 睡眠障害の治療及び予防
DE60132484T2 (de) Chinazolinderivate und -arzneimittel
NZ329312A (en) 2-phenyl, naphthyl, indolyl, benzyl, cycloheptyl or cyclohexylmethyl substituted imidazoline derivatives and medicaments
JPWO2009069828A1 (ja) パーキンソン病の運動合併症または精神症状を改善する薬剤
HK1024631B (en) Use of (+) mefloquine for the treatment of malaria
JP5469707B2 (ja) 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物
TW568785B (en) Pharmaceutical composition for treating or preventing malaria in a subject with reduced side-effects
CN1276753C (zh) 用于治疗类阿片依赖性的吡啶－2－基－甲胺衍生物
KR20240031421A (ko) 메틸페니데이트-전구약물을 포함하는 조성물, 이를 제조 및 사용하는 방법
AU2016234211A1 (en) Therapeutic agent for frontal lobe dysfunction
EP3590511A1 (en) Therapeutic agent for alcohol use disorders

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: VERNALIS RESEARCH LIMITED

Free format text: FORMER NAME: CEREBRUS PHARMACEUTICALS LIMITED

FGA Letters patent sealed or granted (standard patent)